Latest Comments on BioLogic Investment Research's Articles

1. sickofthehype on Acura' Acurox: A Revenue-Deterrent Formulation of Oxycodone: Acurox by Acura Pharmaceuticals. Check out the latest Study 111... more »
2. TheOpioidTruth on Acura' Acurox: A Revenue-Deterrent Formulation of Oxycodone: Name one that cannot be circumvented by taking excessive doses... more »
3. sickofthehype on Acura' Acurox: A Revenue-Deterrent Formulation of Oxycodone: "Where I think they get it wrong is that all of the tamper... more »
4. TheOpioidTruth on Acura' Acurox: A Revenue-Deterrent Formulation of Oxycodone: Actually, this is a very well thought out article. The use of... more »
5. tiger9844 on Acura' Acurox: A Revenue-Deterrent Formulation of Oxycodone: doug, Endo (Durect) is working on one however they are working on... more »
6. back357 on Acura' Acurox: A Revenue-Deterrent Formulation of Oxycodone: Allegedly written by Jeffery S. Cohen and Kevin T. McNamara. ... more »
7. Reddick on Acura' Acurox: A Revenue-Deterrent Formulation of Oxycodone: Who is/are the authors of this write-up? Anybody? more »
8. back357 on Acura' Acurox: A Revenue-Deterrent Formulation of Oxycodone: The article is from a ficticious research company. Do some... more »
9. doug estadt on Acura' Acurox: A Revenue-Deterrent Formulation of Oxycodone: I believe Durect - ticker drrx -are working on the same problem -... more »